Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?

Lam B, Tiniakou E, Zhang XR, Assassi S

BMJ case reports5 Mar 2026

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one woman in her 60s, immune-mediated necrotising myopathy with dysphagia, dysphonia, proximal muscle weakness and creatine kinase elevation occurred after semaglutide use; her symptoms were preceded by a single dose.

    In plain wordsOne woman developed a serious muscle disease after a single dose of semaglutide. One case cannot show cause.

    Outcome
    Not applicableImmune-mediated necrotising myopathy
    Study

    n = 1

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use.
    1 context sentence
    Summary · context
    Her symptoms were preceded by a single dose of semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.